Navigation Links
An invitation to Europe's largest forum on breast cancer
Date:3/25/2008

What is EBCC?

The most exciting breast cancer conference in Europe, it is the only one that involves all the major players in breast cancer. The conference encourages interaction and collaboration between clinicians, scientists and patients in a partnership of equals to talk not just about scientific advances, but also the ethical, social, political, and practical issues associated with caring for patients with breast cancer. EBCC-6 is expected to attract over 5000 delegates from around 90 countries worldwide.

Here is a sample of the new results to be announced at the conference (embargoed to time of presentation at EBCC-6):

  • Hereditary breast cancer a high cost to patient and healthcare provider alike; why women may choose prophylactic mastectomy rather than go through years of stressful screening programmes

  • How obese women are doubly disadvantaged; they do worse in both breast cancer treatment and diagnosis

  • MRI before surgery can lead to better adapted treatment for breast cancer; should this become a standard procedure"

  • Pregnant patients lose out in breast cancer treatment; a new approach is needed

  • New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients

  • Are aromatase inhibitors associated with increased heart problems" Important new evidence

  • New type of drug shrinks primary breast cancer tumours significantly in just six weeks; research provides leads to a new target in breast cancer treatment the stem cell

  • Chemotherapy for metastatic breast cancer: does it work best against sporadic tumours, or those associated with a BRCA1/2 genetic mutation"

  • Breast cancer screening: is an annual mammogram better than a three-yearly one, and should women continue to be screened up to the age of 75" New evidence

  • Can acupuncture provide effective relief from hot flushes in women who are suffering menopause-like symptoms as a result of taking tamoxifen"

  • Results from the largest multi-centre trial to investigate the combination of trastuzumab and neoadjuvant chemotherapy for women with HER2 positive tumours provides surprising new data on safety and efficacy

  • New study reveals that countries could save millions of Euros on follow-up care for breast cancer patients

  • Breast tumours behave differently depending on whether women are older or younger than 70. Is the immune system involved"

Media briefings:

There will be news briefings in English on Wednesday (10am), Thursday (10am) and Friday (9am) and in German on Wednesday (11am).


'/>"/>
Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008
2. SURGEX(TM) Joins the Team of Sponsors for the PGA Tours 2008 Arnold Palmer Invitational Presented by MasterCard
3. Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification
4. CVS, Americas Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges
5. Grassini & Wrinkle Law Firm Are Awarded Largest PI Verdict in Ventura County History
6. Medco Breaks Ground For Worlds Largest Automated Pharmacy
7. Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History
8. AMSA Annual Convention: Largest Gathering of Medical Students Celebrates 58 Years of Student Activism
9. McGraw-Hill Professional Enters Partnership with American College of Physicians, the Worlds Largest Internal Medicine Organization
10. Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists
11. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center ... Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite ... This newest location will provide patients living in the north Houston area (The Woodlands, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The IoT ... and WiFi connectivity are making a huge impact on businesses and individual consumers alike. ... estimates the IoT will have a value anywhere from $4 trillion to $11 trillion ...
(Date:3/23/2017)... ... ... of adults are unaware of the dangers that infectious bacteria play in mouth disease, while ... a day that dentists recommend. The ramifications of improper oral upkeep go far beyond bad ... 164 million hours of work each year due to dental issues. That is why Mediaplanet ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: